Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL29361140 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL30163590 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10542859 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL29438517 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3153130 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL29914630 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL6932335 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL31314302 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL9621416 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL17416909 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6017543-A | OUTER ENVELOPE FREE VIRAL PREPARATION FOR USE IN VACCINATION AGAINST AND IMMUNOTHERAPY OF HUMAN IMMUNODEFICIENCY VIRUS | THE IMMUNE RESPONSE CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
| US-5928930-A | IMMORTALIZING CELLS IMMUNIZED AGAINST NON-INFECTIOUS HUMAN IMMUNODEFICIENCY VIRUS FREE OF OUTER ENVELOPE PROTEINS; FOR MONOCLONAL ANTIBODIES AS VIRICIDES AND VACCINES | IMMUNE RESPONSE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| US-5916806-A | THERE IS ALSO PROVIDED A VACCINE EFFECTIVE AGAINST HIV. | THE IMMUNE RESPONSE CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5895650-A | ADMINISTERING IMMUNOGEN PARTICLES WITHOUT ENVELOPE PROTEINS; VACCINES AGAINST HUMAN IMMUNODEFICIENCY VIRUS | THE IMMUNE RESPONSE CORPORATION (US) | 1999-04-20 | — | — | US | disclosed |
| US-5885578-A | IMMUNIZING A MAMMAL WITH IMMUNOGEN COMPRISING TWO OR MORE HIV PROTEINS, FREE OF OUTER ENVELOPE PROTEIN, WHICH STIMULATES PRODUCTION OF ANTI-HIV ANTIBODIES AND RECOVERING THE PRODUCED ANTI-HIV ANTIBODIES | THE IMMUNE RESPONSE CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5853725-A | Prevention and treatment of retroviral disease | THE IMMUNE RESPONSE CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0317622-B1 | PREVENTION AND TREATMENT OF RETROVIRAL DISEASE | IMMUNE RESPONSE CORP INC (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0685236-A1 | Prevention and treatment of retroviral disease | THE IMMUNE RESPONSE CORPORATION, INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0602761-A1 | Prevention and treatment of retroviral disease | THE IMMUNE RESPONSE CORPORATION, INC. (US) | 1994-06-22 | — | — | EP | disclosed |
| US-5256767-A | Culturing an immunogen devoid of outer envelope proteins; non-infectious intact HIV virus | THE IMMUNE RESPONSE CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0317622-A4 | PREVENTION AND TREATMENT OF RETROVIRAL DISEASE. | IMMUNE RESPONSE CORP INC (US) | 1990-05-14 | — | — | EP | disclosed |
| EP-0317622-A1 | PREVENTION AND TREATMENT OF RETROVIRAL DISEASE. | IMMUNE RESPONSE CORP INC (US) | 1989-05-31 | — | — | EP | disclosed |
| WO-1988009670-A1 | PREVENTION AND TREATMENT OF RETROVIRAL DISEASE | THE IMMUNE RESPONSE CORPORATION, INC. (US) | 1988-12-15 | — | — | WO | disclosed |